20/20 Biolabs, INC. (AIDX) — SEC Filings
Latest SEC filings for 20/20 Biolabs, INC.. Recent EFFECT filing on Apr 10, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View 20/20 Biolabs, INC. on SEC EDGAR
Overview
20/20 Biolabs, INC. (AIDX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Apr 6, 2026: 20/20 Biolabs, Inc. filed an S-1 registration statement on April 6, 2026. This filing indicates the company is preparing to offer its securities to the public. The filing includes various exhibits such as opinions of counsel and consents from accounting firms, alongside the main registration stateme
Sentiment Summary
Across 3 filings, the sentiment breakdown is: 2 neutral, 1 mixed. The dominant filing sentiment for 20/20 Biolabs, INC. is neutral.
Filing Type Overview
20/20 Biolabs, INC. (AIDX) has filed 1 EFFECT, 2 S-1 with the SEC between Dec 2025 to Apr 2026.
Filings by Year
Recent Filings (3)
- EFFECT Filing — EFFECT · Apr 10, 2026
-
20/20 Biolabs Files S-1 for Public Offering
— S-1 · Apr 6, 2026 Risk: medium
20/20 Biolabs, Inc. filed an S-1 registration statement on April 6, 2026. This filing indicates the company is preparing to offer its securities to the public. -
20/20 Biolabs Eyes Nasdaq Direct Listing with AI-Powered Cancer Test
— S-1 · Dec 12, 2025 Risk: high
20/20 Biolabs, Inc. (AIDX) is pursuing a direct listing on Nasdaq, registering 15,130,055 shares for resale by existing stockholders. The company develops and c
Risk Profile
Risk Assessment: Of AIDX's 2 recent filings, 1 were flagged as high-risk, 1 as medium-risk, and 0 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Jonathan Cohen
- Louis A. Bevilacqua, Esq.
Industry Context
The diagnostics industry, particularly in the realm of early disease detection, is characterized by rapid technological advancement and increasing competition. The multi-cancer early detection (MCED) segment, where 20/20 Biolabs operates with its OneTest for Cancer, is a high-growth area driven by the demand for less invasive and more effective screening methods. Key trends include the integration of artificial intelligence (AI) and machine learning into diagnostic platforms, and the development of blood-based tests utilizing novel biomarkers.
Top Tags
ipo (1) · registration-statement (1) · sec-filing (1) · Biotechnology (1) · Cancer Diagnostics (1) · AI in Healthcare (1) · Direct Listing (1) · Medical Devices (1) · Emerging Growth Company (1) · Laboratory Services (1)
Key Numbers
- Filing Date: 2026-04-06 — Date 20/20 Biolabs, Inc. filed its S-1 registration statement.
- Starting price of OneTest for Cancer: $200 — Positions OneTest as an affordable multi-cancer early detection test
- Shares of common stock registered for resale: 15,130,055 — Represents the total shares available for sale by selling stockholders in the direct listing
- Percentage of revenues from OneTest for Cancer: 87% — For the nine months ended September 30, 2025, indicating primary commercial focus
- Percentage of revenues from COVID-19 testing: 0% — For the year ended December 31, 2024, down from 18% in 2023, indicating business shift
- Percentage of revenues from BioCheck: 9% — For the nine months ended September 30, 2025
- Percentage of revenues from CLIAx: 4% — For the nine months ended September 30, 2025
- Number of soldiers, sailors, airmen, and marines screened by HunterSeven Foundation: 1,000 — Using OneTest for Cancer in 2025, leading to identification of at least 18 cancers
- Number of cancers identified by OneTest for Cancer: 18 — Among 1,000 veterans screened by HunterSeven Foundation in 2025
Related Companies
Frequently Asked Questions
What are the latest SEC filings for 20/20 Biolabs, INC. (AIDX)?
20/20 Biolabs, INC. has 3 recent SEC filings from Dec 2025 to Apr 2026, including 2 S-1, 1 EFFECT. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of AIDX filings?
Across 3 filings, the sentiment breakdown is: 2 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find 20/20 Biolabs, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all 20/20 Biolabs, INC. (AIDX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for 20/20 Biolabs, INC.?
Financial highlights for 20/20 Biolabs, INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for AIDX?
The investment thesis for AIDX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at 20/20 Biolabs, INC.?
Key executives identified across 20/20 Biolabs, INC.'s filings include Jonathan Cohen, Louis A. Bevilacqua, Esq..
What are the main risk factors for 20/20 Biolabs, INC. stock?
Of AIDX's 2 assessed filings, 1 were flagged high-risk, 1 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from 20/20 Biolabs, INC.?
Forward guidance and predictions for 20/20 Biolabs, INC. are extracted from SEC filings as they are enriched.